CMS spent more than $18B in four years on accelerated approvals with incomplete confirmatory trials, inspector general finds
The battle over whether and how to reform the FDA’s accelerated approval pathway is heating up again, just as the Senate punted any talks until …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
